| pubmed-article:8395482 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8395482 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:8395482 | lifeskim:mentions | umls-concept:C0023828 | lld:lifeskim |
| pubmed-article:8395482 | lifeskim:mentions | umls-concept:C0035331 | lld:lifeskim |
| pubmed-article:8395482 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:8395482 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:8395482 | lifeskim:mentions | umls-concept:C2348438 | lld:lifeskim |
| pubmed-article:8395482 | lifeskim:mentions | umls-concept:C0050164 | lld:lifeskim |
| pubmed-article:8395482 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:8395482 | pubmed:dateCreated | 1993-9-30 | lld:pubmed |
| pubmed-article:8395482 | pubmed:abstractText | Human cytomegalovirus (HCMV) is an important pathogen in the immunocompromised patient. CMV retinitis is a leading cause of blindness in patients with AIDS. Ganciclovir and foscarnet are currently the treatments being used for this retinitis, but they both have major toxicities when used systemically. Intravitreal therapy with ganciclovir has been used in some patients who cannot tolerate systemic treatment. The major problem with this modality is the necessity for administration of between 1 and 3 intravitreal injections per eye per week. 2'-nor-cyclic GMP is a nucleotide analog, a cyclic phosphate derivative of ganciclovir. Neutral salts of the compound are extremely water soluble, and the charged phosphate group at neutral pH make it an ideal candidate for encapsulation into a multivesicular liposome system. | lld:pubmed |
| pubmed-article:8395482 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395482 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8395482 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395482 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8395482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8395482 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8395482 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8395482 | pubmed:issn | 0146-0404 | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:AstinJ KJK | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:TolmanR LRL | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:WileyC ACA | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:KarkasJ DJD | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:MunguiaDD | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:ListhausA DAD | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:Bergeron-Lynn... | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:Flores-Aguila... | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:ShakibaSS | lld:pubmed |
| pubmed-article:8395482 | pubmed:author | pubmed-author:VuongCC | lld:pubmed |
| pubmed-article:8395482 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8395482 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:8395482 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8395482 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8395482 | pubmed:pagination | 2903-10 | lld:pubmed |
| pubmed-article:8395482 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:meshHeading | pubmed-meshheading:8395482-... | lld:pubmed |
| pubmed-article:8395482 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8395482 | pubmed:articleTitle | Evaluation of retinal toxicity and liposome encapsulation of the anti-CMV drug 2'-nor-cyclic GMP. | lld:pubmed |
| pubmed-article:8395482 | pubmed:affiliation | Department of Ophthalmology, University of California, San Diego, La Jolla 92093-0946. | lld:pubmed |
| pubmed-article:8395482 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8395482 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8395482 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8395482 | lld:pubmed |
